JPH06508025A - 癌胎児性抗原を発現する組換えウイルスとその使用方法 - Google Patents
癌胎児性抗原を発現する組換えウイルスとその使用方法Info
- Publication number
- JPH06508025A JPH06508025A JP4512025A JP51202592A JPH06508025A JP H06508025 A JPH06508025 A JP H06508025A JP 4512025 A JP4512025 A JP 4512025A JP 51202592 A JP51202592 A JP 51202592A JP H06508025 A JPH06508025 A JP H06508025A
- Authority
- JP
- Japan
- Prior art keywords
- cea
- virus
- recombinant
- nyc
- vaccinia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 title claims description 138
- 241000700605 Viruses Species 0.000 title claims description 115
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 title claims 17
- 210000004027 cell Anatomy 0.000 claims description 126
- 206010028980 Neoplasm Diseases 0.000 claims description 94
- 241000700618 Vaccinia virus Species 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 45
- 201000011510 cancer Diseases 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 102000000588 Interleukin-2 Human genes 0.000 claims description 22
- 108010002350 Interleukin-2 Proteins 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 17
- 230000028993 immune response Effects 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 9
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 9
- 230000008512 biological response Effects 0.000 claims description 8
- 210000000987 immune system Anatomy 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 230000002238 attenuated effect Effects 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000598171 Human adenovirus sp. Species 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 241000701822 Bovine papillomavirus Species 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 241000277263 Salmo Species 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 121
- 206010046865 Vaccinia virus infection Diseases 0.000 description 76
- 208000007089 vaccinia Diseases 0.000 description 76
- 241000699670 Mus sp. Species 0.000 description 58
- 241001465754 Metazoa Species 0.000 description 52
- 230000003053 immunization Effects 0.000 description 37
- 238000002649 immunization Methods 0.000 description 37
- 241000282693 Cercopithecidae Species 0.000 description 33
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 210000002966 serum Anatomy 0.000 description 28
- 108020004414 DNA Proteins 0.000 description 27
- 239000000427 antigen Substances 0.000 description 26
- 108091007433 antigens Proteins 0.000 description 26
- 102000036639 antigens Human genes 0.000 description 26
- 238000002255 vaccination Methods 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 230000004044 response Effects 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 229960005486 vaccine Drugs 0.000 description 18
- 210000004698 lymphocyte Anatomy 0.000 description 17
- 230000004614 tumor growth Effects 0.000 description 17
- 239000012634 fragment Substances 0.000 description 16
- 210000004881 tumor cell Anatomy 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 108010058846 Ovalbumin Proteins 0.000 description 13
- 230000012010 growth Effects 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 238000011081 inoculation Methods 0.000 description 13
- 229940092253 ovalbumin Drugs 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 208000009956 adenocarcinoma Diseases 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 229920000742 Cotton Polymers 0.000 description 11
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 11
- 230000002494 anti-cea effect Effects 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 102000055277 human IL2 Human genes 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 229960004397 cyclophosphamide Drugs 0.000 description 10
- 230000002163 immunogen Effects 0.000 description 10
- 230000009257 reactivity Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 208000029742 colonic neoplasm Diseases 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 9
- 108020004440 Thymidine kinase Proteins 0.000 description 8
- 238000003125 immunofluorescent labeling Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 102000006601 Thymidine Kinase Human genes 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000002356 single layer Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 101150045267 CEA gene Proteins 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 239000013615 primer Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 239000004677 Nylon Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000012045 crude solution Substances 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229920001778 nylon Polymers 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 230000005951 type IV hypersensitivity Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 108020003215 DNA Probes Proteins 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- 102000004533 Endonucleases Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000002101 lytic effect Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000000879 optical micrograph Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000003656 tris buffered saline Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101000653542 Homo sapiens Transcription factor-like 5 protein Proteins 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000008348 humoral response Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 235000010585 Ammi visnaga Nutrition 0.000 description 2
- 244000153158 Ammi visnaga Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 101150003725 TK gene Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000009021 pre-vaccination Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 241000726103 Atta Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 241000201835 Froelichia floridana Species 0.000 description 1
- 241001669573 Galeorhinus galeus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 101150073928 MCA3 gene Proteins 0.000 description 1
- 208000004585 Macrostomia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 101100355584 Mus musculus Rad51 gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241001467018 Typhis Species 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000017419 commissural facial cleft Diseases 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 102000051838 human TCFL5 Human genes 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036332 sexual response Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (24)
- 1.癌胎児性抗原(CEA)遺伝子が挿入されたワクシニアウイルスからなる組 換えウイルスであって; このウイルスに感染した細胞の表面にCEAを発現し、かつCE4およびCEA を発現する細胞に対して特異的な生体内免疫応答を誘発する組換えウイルス。
- 2.前記ワクシニアウイルスがV−WR株のウイルスである請求の範囲第1項記 載の組換えウイルス。
- 3.前記ワクシニアウイルスがNYC株のウイルスである請求の範囲第1項記載 の組換えウイルス。
- 4.前記ワクシニアウイルスが他の弱毒ヒトワクシニアウイルス株で組換えられ ている請求の範囲第1項記載の組換えウイルス。
- 5.前記CEAが単一または多数の免疫優性T細胞エピトープからなる請求の範 囲第1項記載の組換えウイルス。
- 6.rV−CEAで構成されている組換え癌胎児性抗原/ワクシニアウイルス( ATCC受託番号VR2323)。
- 7.前記ワクシニアウイルスがCEAの発現を増大するプロモーターを含有して いる請求の範囲第1項記載の組換えウイルス。
- 8.癌の細胞がCEAを発現する癌にかかっている患者に請求の範囲第1項記載 の組換えウイルスを投与することからなる該患者の治療方法。
- 9.前記癌細胞が胃腸、乳房、すい臓、膀胱、卵巣、肺または前立腺の癌細胞で ある請求の範囲第8項記載の方法。
- 10.前記癌細胞が、CEAエピトープを発現する上皮誘導癌細胞からなる請求 の範囲第8項記載の方法。
- 11.さらに、前記組換えウイルスとともに、生体応答調節剤を投与することか らなる請求の範囲第8項記載の方法。
- 12.前記生体応答調節剤がインターロイキン−2(IL−2)、インターロイ キン−6(IL−6)、インターフェロン、腫瘍壊死因子(TNF)およびシク ロホスフアミドからなる群から選択される請求の範囲第11項記載の方法。
- 13.さらに、前記組換えウイルスとともにアジュバントを投与することからな る請求の範囲第8項記載の方法。
- 14.癌胎児性抗原(ECA)遺伝子が挿入されているバキュウイルス、サルモ ネラ属の細菌、ヒトアデノウイルス、SV40およびウシ乳頭腫ウイルスからな る群から選択されるウイルスからなる組換えウイルスであって; これに感染した細胞の表面にCEAを発現し、かつCEAまたはCEAを発現す る細胞に対して特異的な生体内免疫応答を誘発する組換えウイルス。
- 15.癌の細胞がCEAを発現する癌にかかっている患者に請求の範囲第14項 記載の組換えウイルスを投与することからなる該患者の治療方法。
- 16.癌細胞の定着と増殖を防止するために、CEAに対する哺乳類の免疫系を 刺激する方法であって; 前記哺乳類に対し、請求項1記載の組換えウイルスを前記刺激を行うのに十分な 量で投与することからなる方法。
- 17.前記ワクシニアウイルスがNYC株のウイルスである請求の範囲第16項 記載の方法。
- 18.前記ワクシニアウイルスが、弱毒ヒトワクシニアウイルス株で組換えられ ている請求の範囲第16項記載の方法。
- 19.さらに、前記組換えウイルスとともに生体応答調節剤を投与することから なる請求の範囲第16項記載の方法。
- 20.前記生体応答調節剤が、インターロイキン−2(IL−2)、インターロ イキン−6(IL−6)、インタ−フェロン、腫瘍壊死因子(TNF)およびシ クロホスフアミドからなる群から選択される請求の範囲第19項記載の方法。
- 21.さらに、前記組換えウイルスとともにアジュバントを投与することからな る請求の範囲第16項記載の方法。
- 22.癌細胞の定着と増殖を防止するために、CEAに対する哺乳類の免疫系を 刺激する方法であって; 前記哺乳類に対し、請求の範囲第14項記載の組換えウイルスを前記刺激を行う のに充分な量で投与することからなる方法。
- 23.請求の範囲第1項記載の組換えウイルス、および医薬として許容される希 釈剤、担体または賦形剤担体からなる医薬組成物。
- 24.請求の範囲第14項記載の組換えウイルス、および医薬として許容される 希釈剤、担体または賦形剤担体からなる医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69502491A | 1991-05-06 | 1991-05-06 | |
US695,024 | 1991-05-06 | ||
US87964992A | 1992-05-06 | 1992-05-06 | |
US879,649 | 1992-05-06 | ||
PCT/US1992/003843 WO1992019266A1 (en) | 1991-05-06 | 1992-05-06 | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06508025A true JPH06508025A (ja) | 1994-09-14 |
JP3399943B2 JP3399943B2 (ja) | 2003-04-28 |
Family
ID=27105497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51202592A Expired - Lifetime JP3399943B2 (ja) | 1991-05-06 | 1992-05-06 | 癌胎児性抗原を発現する組換えウイルスとその使用方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US5698530A (ja) |
EP (1) | EP0584266B1 (ja) |
JP (1) | JP3399943B2 (ja) |
AT (1) | ATE248924T1 (ja) |
AU (1) | AU674492B2 (ja) |
CA (1) | CA2102623C (ja) |
DE (1) | DE69233186T2 (ja) |
DK (1) | DK0584266T3 (ja) |
ES (1) | ES2206446T3 (ja) |
WO (1) | WO1992019266A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11509199A (ja) * | 1995-07-10 | 1999-08-17 | セリオン バイオロジクス コーポレイション | 前立腺特異的抗原(psa)に対する免疫応答の発生 |
JP2001515052A (ja) * | 1997-08-13 | 2001-09-18 | ザ ユーエイビー リサーチ ファンデーション | 遺伝子ベクターの局所施用によるワクチン接種 |
JP2020511139A (ja) * | 2017-03-17 | 2020-04-16 | バクシム アクチェンゲゼルシャフト | がん免疫療法のための新規pd−l1標的dnaワクチン |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
AT399656B (de) * | 1993-03-19 | 1995-06-26 | Boehringer Ingelheim Int | Verfahren zur herstellung von krebsvakzinen |
US6093700A (en) * | 1995-05-11 | 2000-07-25 | Thomas Jefferson University | Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF |
US6045802A (en) * | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
EP1016418B1 (en) * | 1994-10-03 | 2009-12-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Host cell comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |
US5612030A (en) | 1995-01-17 | 1997-03-18 | University Of Kentucky Research Foundation | Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
US5977316A (en) * | 1995-01-17 | 1999-11-02 | The Board Of Trustees Of The University Of Kentucky | Monoclonal antibody 1A7 and related polypeptides |
US5935821A (en) * | 1995-01-17 | 1999-08-10 | Board Of Trustees Of The University Of Kentucky | Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
US6001349A (en) * | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
EP0811073B1 (en) * | 1995-02-24 | 2007-01-24 | The Trustees Of The University Of Pennsylvania | Use of immune modulators for making medicaments ot inhibit immune responses against co-administered recombinant viruses |
US6372208B1 (en) | 1999-09-28 | 2002-04-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant virus |
US6251957B1 (en) | 1995-02-24 | 2001-06-26 | Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant virus |
US5872154A (en) * | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
US5480640A (en) * | 1995-05-02 | 1996-01-02 | Schering Corporation | Alpha interferon for treating prostate cancer |
WO1998004727A1 (en) * | 1996-07-25 | 1998-02-05 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
AU5805798A (en) * | 1996-12-31 | 1998-07-31 | Wistar Institute, The | Recombinant adenoviral vector expressing antigens associated with colorectal tumors |
DE19716892C1 (de) * | 1997-04-22 | 1998-09-03 | Gsf Forschungszentrum Umwelt | Expression von Immunglobulin-Zytokin-Fusionsproteinen in malignen B-Zellen |
US6120806A (en) * | 1997-06-25 | 2000-09-19 | Whitmire; David R. | Oral formulations for controlled release of alcohol deterrents |
US6756038B1 (en) | 1997-10-10 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Agonist and antagonist peptides of carcinoembryonic antigen (CEA) |
AU745863B2 (en) * | 1997-10-10 | 2002-04-11 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Agonist and antagonist peptides of carcinoembryonic antigen (CEA) |
US6355244B1 (en) | 1997-11-17 | 2002-03-12 | University Of Kentucky Research Foundation | Methods and compositions for the treatment of psoriasis |
US6506385B1 (en) | 1998-04-17 | 2003-01-14 | Embrex, Inc. | Live vaccines and methods of treatment therewith |
US7148035B1 (en) | 1998-11-18 | 2006-12-12 | Oxford Biomedica (Uk) Limited | Polypeptide |
US6896881B1 (en) * | 1999-09-24 | 2005-05-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
CA2388337C (en) | 1999-10-22 | 2013-01-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
CA2408328C (en) | 2000-05-10 | 2012-04-17 | Aventis Pasteur Limited | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
AU2002364161A1 (en) * | 2001-12-12 | 2003-06-23 | Aventis Pasteur Limited | Enhancement of the immune response using cd36-binding domain |
EP1467751A2 (en) * | 2002-01-17 | 2004-10-20 | Pharmexa A/S | Immunogenic cea |
US6949629B2 (en) * | 2002-03-13 | 2005-09-27 | Aspenbio, Inc. | Methods for purifying selected CEA family member proteins |
AU2003223527B2 (en) * | 2002-04-09 | 2009-01-15 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
AU2003278036B2 (en) * | 2002-10-22 | 2009-12-10 | Aventis Pasteur Limited | Anti-cancer vaccines and high-dose cytokines as adjuvants |
EP1597370B1 (en) * | 2003-02-13 | 2006-06-28 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof |
US20060286114A1 (en) * | 2003-08-22 | 2006-12-21 | Luigi Aurisicchio | Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof |
EP1670926B1 (en) * | 2003-10-08 | 2011-04-20 | Sanofi Pasteur Limited | Modified cea /b7 vector |
NZ549048A (en) * | 2004-02-11 | 2009-04-30 | Angeletti P Ist Richerche Bio | Carcinoembryonic antigen fusion proteins and uses thereof |
AU2009223727B2 (en) | 2008-03-14 | 2014-09-11 | Sanofi Pasteur Biologics, Llc | Replication-defective flavivirus vaccines and vaccine vectors |
US20120263754A1 (en) | 2011-02-15 | 2012-10-18 | Immune Design Corp. | Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines |
EA027236B1 (ru) | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
US9895435B2 (en) | 2012-05-16 | 2018-02-20 | Immune Design Corp. | Vaccines for HSV-2 |
WO2014140938A2 (en) | 2013-03-14 | 2014-09-18 | Centre Hospitalier Universitaire Vaudois | Immunological methods |
US9725494B2 (en) * | 2013-05-17 | 2017-08-08 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble CD27 (sCD27) and the use thereof |
EA035259B1 (ru) | 2014-02-14 | 2020-05-21 | Иммьюн Дизайн Корп. | Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции |
AU2015289773A1 (en) | 2014-07-15 | 2017-02-02 | Immune Design Corp. | Prime-boost regimens with a TLR4 agonist adjuvant and a lentiviral vector |
WO2017120204A2 (en) | 2016-01-05 | 2017-07-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination of histone deacetylase inhibitor and immunotherapy |
WO2017136342A1 (en) | 2016-02-02 | 2017-08-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells |
WO2017181148A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Icos ligand variant immunomodulatory proteins and uses thereof |
SG11201808783XA (en) | 2016-04-15 | 2018-11-29 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
CA3032120A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
CN110809581A (zh) | 2017-03-16 | 2020-02-18 | 高山免疫科学股份有限公司 | Pd-l2变体免疫调节蛋白及其用途 |
SG11201907769XA (en) | 2017-03-16 | 2019-09-27 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
HRP20231382T1 (hr) | 2017-03-16 | 2024-02-16 | Alpine Immune Sciences, Inc. | Pd-l1 varijanta imunomodulacijskih proteina i njihova upotreba |
IL269534B1 (en) | 2017-03-30 | 2024-09-01 | Univ Queensland | Chimeric molecules and their uses |
US12076369B2 (en) | 2017-09-01 | 2024-09-03 | The Frances Crick Institute Limited | Immunoregulatory molecules and uses therefor |
EP3694870A1 (en) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
EA202090974A1 (ru) | 2017-10-18 | 2020-08-05 | Элпайн Иммьюн Сайенсиз, Инк. | Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы |
SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
US12065476B2 (en) | 2018-06-15 | 2024-08-20 | Alpine Immune Sciences, Inc. | PD-1 variant immunomodulatory proteins and uses thereof |
KR20210089146A (ko) | 2018-09-19 | 2021-07-15 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 변이체 cd80 단백질 및 관련 구축물의 방법 및 용도 |
KR20210135987A (ko) | 2018-11-30 | 2021-11-16 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Cd86 변이체 면역조절 단백질 및 그의 용도 |
WO2020214867A1 (en) | 2019-04-17 | 2020-10-22 | Alpine Immune Sciences, Inc. | Methods and uses of variant icos ligand (icosl) fusion proteins |
WO2021226553A2 (en) | 2020-05-08 | 2021-11-11 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
CA3216795A1 (en) | 2021-05-07 | 2022-11-10 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722848A (en) * | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
GB8508845D0 (en) * | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
DE3787864T2 (de) * | 1986-08-13 | 1994-02-10 | Miles Inc | Karzinoembryonisches Antigen kodierende cDNS. |
WO1989001973A2 (en) * | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
-
1992
- 1992-05-06 ES ES92913153T patent/ES2206446T3/es not_active Expired - Lifetime
- 1992-05-06 JP JP51202592A patent/JP3399943B2/ja not_active Expired - Lifetime
- 1992-05-06 EP EP92913153A patent/EP0584266B1/en not_active Expired - Lifetime
- 1992-05-06 WO PCT/US1992/003843 patent/WO1992019266A1/en active IP Right Grant
- 1992-05-06 CA CA002102623A patent/CA2102623C/en not_active Expired - Lifetime
- 1992-05-06 AU AU20060/92A patent/AU674492B2/en not_active Expired
- 1992-05-06 DK DK92913153T patent/DK0584266T3/da active
- 1992-05-06 AT AT92913153T patent/ATE248924T1/de active
- 1992-05-06 DE DE69233186T patent/DE69233186T2/de not_active Expired - Lifetime
-
1994
- 1994-07-01 US US08/270,106 patent/US5698530A/en not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11509199A (ja) * | 1995-07-10 | 1999-08-17 | セリオン バイオロジクス コーポレイション | 前立腺特異的抗原(psa)に対する免疫応答の発生 |
JP2006197938A (ja) * | 1995-07-10 | 2006-08-03 | Therion Biologics Corp | 前立腺特異的抗原(psa)に対する免疫応答の発生 |
JP2001515052A (ja) * | 1997-08-13 | 2001-09-18 | ザ ユーエイビー リサーチ ファンデーション | 遺伝子ベクターの局所施用によるワクチン接種 |
JP2020511139A (ja) * | 2017-03-17 | 2020-04-16 | バクシム アクチェンゲゼルシャフト | がん免疫療法のための新規pd−l1標的dnaワクチン |
Also Published As
Publication number | Publication date |
---|---|
EP0584266A1 (en) | 1994-03-02 |
WO1992019266A1 (en) | 1992-11-12 |
DK0584266T3 (da) | 2003-12-29 |
CA2102623C (en) | 2003-04-22 |
AU674492B2 (en) | 1997-01-02 |
DE69233186D1 (de) | 2003-10-09 |
CA2102623A1 (en) | 1992-11-07 |
DE69233186T2 (de) | 2004-06-03 |
EP0584266B1 (en) | 2003-09-03 |
US5698530A (en) | 1997-12-16 |
ATE248924T1 (de) | 2003-09-15 |
AU2006092A (en) | 1992-12-21 |
ES2206446T3 (es) | 2004-05-16 |
EP0584266A4 (en) | 1995-04-05 |
JP3399943B2 (ja) | 2003-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06508025A (ja) | 癌胎児性抗原を発現する組換えウイルスとその使用方法 | |
Kaufman et al. | A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA) | |
Robbins et al. | Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line | |
JP3907698B2 (ja) | 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物 | |
JP4776852B2 (ja) | 癌抗原nyeso−1由来の新規mhcクラスii拘束t細胞エピトープ | |
ES2222728T3 (es) | Procedimiento de vacunacion terapeutica. | |
Kantor et al. | Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine | |
ES2373055T3 (es) | Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno. | |
JP5291641B2 (ja) | 癌抗原及びその利用 | |
CA2245702A1 (en) | Human cancer antigen of tyrosinase-related protein 1 and 2 and genes encoding same | |
AU619448B2 (en) | Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor | |
JP2002515734A (ja) | 遺伝子改変された樹状細胞により媒介される免疫刺激 | |
US7414108B2 (en) | Composition and method for producing an immune response against tumor-related antigens | |
BG106028A (bg) | Имунотерапия на рак чрез експресия на скъсен туморен или тумор-асоцииран антиген | |
JPH11507804A (ja) | 癌自己関連抗原特異的ヒト細胞障害性t細胞の産生とその使用 | |
JPH09503740A (ja) | 組換えウイルス・ベクターによる選択された腫瘍増殖の阻害 | |
JP2005511047A (ja) | 潜伏期膜タンパク質に対する抗体およびそれらの使用 | |
CN102884194B (zh) | 含增强免疫应答的Fc融合蛋白的方法和组合物 | |
EP1572231A2 (en) | Cancer immunotherapy using polycomb proteins | |
CN110054698B (zh) | 抗cd19抗体的新型cd19-car载体的构建及应用 | |
US20060286114A1 (en) | Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof | |
JP2002501369A (ja) | Fivワクチン | |
ES2371394T3 (es) | Antígenos de cáncer y su utilización. | |
HODGE et al. | CARCEVOEMBRYONIC ANTIGEN (CEA) AS A MODEL FOR IMMUNOTHERAPY USING RECOMBINANT VACCINES | |
CN114641315A (zh) | 癌症免疫疗法中的asc斑点 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090221 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090221 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100221 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100221 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110221 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120221 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130221 Year of fee payment: 10 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130221 Year of fee payment: 10 |